These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25339360)

  • 1. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011.
    Collins PW; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Blood; 2014 Nov; 124(23):3389-97. PubMed ID: 25339360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
    Hay CRM; Palmer BP; Chalmers EA; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Collins PW
    Haemophilia; 2015 Mar; 21(2):219-226. PubMed ID: 25382829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S; Cannavò A; Gouw SC; Rosendaal FR; van der Bom JG
    J Thromb Haemost; 2018 Jun; 16(6):1055-1068. PubMed ID: 29665204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
    Calvez T; Chambost H; d'Oiron R; Dalibard V; Demiguel V; Doncarli A; Gruel Y; Huguenin Y; Lutz P; Rothschild C; Vinciguerra C; Goudemand J;
    Haematologica; 2018 Jan; 103(1):179-189. PubMed ID: 29025913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.
    Calvez T; Chambost H; Claeyssens-Donadel S; d'Oiron R; Goulet V; Guillet B; Héritier V; Milien V; Rothschild C; Roussel-Robert V; Vinciguerra C; Goudemand J;
    Blood; 2014 Nov; 124(23):3398-408. PubMed ID: 25253771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunogenicity of ReFacto AF (moroctocog alfa AF-CC) in previously untreated patients with haemophilia A in the United Kingdom.
    Mathias MC; Collins PW; Palmer BP; Chalmers E; Alamelu J; Richards M; Will A; Hay CRM;
    Haemophilia; 2018 Nov; 24(6):896-901. PubMed ID: 30004617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.
    Gouw SC; van den Berg HM; le Cessie S; van der Bom JG
    J Thromb Haemost; 2007 Jul; 5(7):1383-90. PubMed ID: 17456190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
    Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
    Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation.
    Lusher J; Abildgaard C; Arkin S; Mannucci PM; Zimmermann R; Schwartz L; Hurst D
    J Thromb Haemost; 2004 Apr; 2(4):574-83. PubMed ID: 15102011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A.
    Yoshioka A; Fukutake K; Takamatsu J; Shirahata A;
    Int J Hematol; 2003 Dec; 78(5):467-74. PubMed ID: 14704043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
    Rota M; Cortesi PA; Steinitz-Trost KN; Reininger AJ; Gringeri A; Mantovani LG
    Blood Coagul Fibrinolysis; 2017 Dec; 28(8):627-637. PubMed ID: 28678027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.
    Peyvandi F; Mannucci PM; Garagiola I; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Hanagavadi S; Varadarajan R; Karimi M; Manglani MV; Ross C; Young G; Seth T; Apte S; Nayak DM; Santagostino E; Mancuso ME; Sandoval Gonzalez AC; Mahlangu JN; Bonanad Boix S; Cerqueira M; Ewing NP; Male C; Owaidah T; Soto Arellano V; Kobrinsky NL; Majumdar S; Perez Garrido R; Sachdeva A; Simpson M; Thomas M; Zanon E; Antmen B; Kavakli K; Manco-Johnson MJ; Martinez M; Marzouka E; Mazzucconi MG; Neme D; Palomo Bravo A; Paredes Aguilera R; Prezotti A; Schmitt K; Wicklund BM; Zulfikar B; Rosendaal FR
    N Engl J Med; 2016 May; 374(21):2054-64. PubMed ID: 27223147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of recombinant factor VIII products in patients with hemophilia A.
    Musso R
    Drugs Today (Barc); 2008 Oct; 44(10):735-50. PubMed ID: 19137127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
    Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
    Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A.
    Sharathkumar A; Lillicrap D; Blanchette VS; Kern M; Leggo J; Stain AM; Brooker L; Carcao MD
    J Thromb Haemost; 2003 Jun; 1(6):1228-36. PubMed ID: 12871324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more.
    Iorio A; Fischer K; Makris M
    Br J Haematol; 2017 Jul; 178(1):20-31. PubMed ID: 28387451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII brand and immunogenicity.
    Ragni MV
    Blood; 2014 Nov; 124(23):3337-8. PubMed ID: 25431473
    [No Abstract]   [Full Text] [Related]  

  • 18. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.
    Cannavò A; Valsecchi C; Garagiola I; Palla R; Mannucci PM; Rosendaal FR; Peyvandi F;
    Blood; 2017 Mar; 129(10):1245-1250. PubMed ID: 28034891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance.
    Rothschild C; Laurian Y; Satre EP; Borel Derlon A; Chambost H; Moreau P; Goudemand J; Parquet A; Peynet J; Vicariot M; Beurrier P; Claeyssens S; Durin A; Faradji A; Fressinaud E; Gaillard S; Guérin V; Guérois C; Pernod G; Pouzol P; Schved JF; Gazengel C
    Thromb Haemost; 1998 Nov; 80(5):779-83. PubMed ID: 9843171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies.
    Di Minno MN; Marchesini E; Valdrè L
    Blood; 2015 Jun; 125(24):3819-21. PubMed ID: 26069336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.